The Human Tumor Atlas Network charts the roadmap for advancing spatial omics

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

In the face of the unknown, two cancer center leaders discuss planning for the future, recovering from setbacks, and holding on to what they still have.

September 12, 2025

Vol.51 No.33

By Claire Marie Porter, Jacquelyn Cobb and Paul Goldberg

NCAB approves five reissue concepts

The National Cancer Advisory Board approved five reissue concepts at a meeting Sept. 4.

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

As NIH and NCI funding is negotiated in Congress, Paul W. Thurman felt compelled to crunch some numbers. He compared the U.S.’s cumulative funding for NCI to the funding slated for ICE—the latter of which vastly outweighs the former—and asked whether the funding priorities of the federal government are properly representing the nation’s mortality.

September 10, 2025

Vol.51 No.32

Capitol Hill

House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts

The House is on track to join the Senate in rejecting the Trump administration’s budget proposal that would cut NIH by $18 billion.

September 05, 2025

Vol.51 No.32

By Jacquelyn Cobb and Paul Goldberg

Guest Editorial

Curing cancer or curbing immigration: A question of national morality and priority

In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding.

Julie Bauman named deputy chair of NRG Oncology’s NCORP research program, Ryan Burri named vice chair of Veteran Affairs research

Julie BaumanRyan BurriNRG Oncology, an NCI National Clinical Trials Network group focused on multi-center clinical research, appointed Julie Bauman as deputy chair of the Community Oncology Research Program.

September 05, 2025

Vol.51 No.32

The Human Tumor Atlas Network charts the roadmap for advancing spatial omics

YOU MAY BE INTERESTED IN

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

NCAB approves five reissue concepts

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts

Curing cancer or curbing immigration: A question of national morality and priority

Julie Bauman named deputy chair of NRG Oncology’s NCORP research program, Ryan Burri named vice chair of Veteran Affairs research

Renew today!

Subscriber content

Never miss an issue!

Login

The Human Tumor Atlas Network charts the roadmap for advancing spatial omics

YOU MAY BE INTERESTED IN

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

NCAB approves five reissue concepts

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99MHouse joins Senate in rejecting Trump’s proposed 40% NIH cuts

Curing cancer or curbing immigration: A question of national morality and priority

Julie Bauman named deputy chair of NRG Oncology’s NCORP research program, Ryan Burri named vice chair of Veteran Affairs research

Never miss an issue!

Login

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts